
Vaxart has announced topline data from its phase 2 challenge study which assessed its oral tablet monovalent norovirus vaccine candidate. …

Takeda Pharmaceuticals (TSE: 4502) has announced that the first patient has received a dosage of their norovirus vaccine candidate, TAK-214, …

Takeda Pharmaceutical Company is to pay $60 million upfront to buy private US biopharma firm LigoCyte Pharmaceuticals in the next …

